Filing Flows

Filing Flows › Companies › Lyell Immunopharma › Cash flow

Lyell Immunopharma cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$34.6M in Q3 2026 · −$140M over twelve months

Operating cash flow−$34.6M
Capital spending−$66K
Free cash flow−$34.6M

Analysis

In Q3 2026, Lyell Immunopharma generated −$34.6M of operating cash flow and spent $66K on capital projects, leaving free cash flow of −$34.6M. That is $6.0M less than in Q3 2025 (−$28.6M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$139M; the largest uses were operating cash flow ($139M), capital spending ($715K); besides operations, cash came from other investing ($55.9M), other financing ($52.4M); the cash balance fell by $31.5M.

Operating cash flow was −$34.6M against net income of −$45.5M. The largest differences: accrued liabilities +$6.2M, stock-based pay +$4.5M, depreciation & amortization +$2.1M.

Free cash flow

Lyell Immunopharma: free cash flow by quarterLyell Immunopharma: free cash flow by quarter−$47.3MQ4 2024−$55.0MQ1 2025−$34.6MQ2 2025−$28.6MQ3 2025−$32.6MQ4 2025−$38.6MQ1 2026−$34.2MQ2 2026−$34.6MQ3 2026
Operating cash flow less capital spending.
Lyell Immunopharma: operating cash flow against capital spendingLyell Immunopharma: operating cash flow against capital spendingOperating cash flowCapital spending−$47.2M$44KQ4 2024−$54.7M$246KQ1 2025−$34.5M$168KQ2 2025−$28.6M$62KQ3 2025−$32.3M$304KQ4 2025−$38.5M$89KQ1 2026−$33.9M$256KQ2 2026−$34.6M$66KQ3 2026
Latest (Q3 2026): Operating cash flow −$34.6M, Capital spending $66K.

Capital allocation, year by year

Lyell Immunopharma: where the cash came from (up) and went (down), by fiscal yearLyell Immunopharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$126MFY2021: Shares issued $401MFY2021: Capital spending −$65.5M$401MFY2021FY2022: Operating cash flow −$170MFY2022: Shares issued $9.6MFY2022: Capital spending −$24.3M$9.6MFY2022FY2023: Operating cash flow −$164MFY2023: Shares issued $306KFY2023: Capital spending −$2.7M$306KFY2023FY2024: Operating cash flow −$162MFY2024: Shares issued $154KFY2024: Capital spending −$464K$154KFY2024FY2025: Operating cash flow −$150MFY2025: Shares issued $50.0MFY2025: Asset sales $287KFY2025: Capital spending −$780K$50.3MFY2025
Over these 5 years operating cash flow totalled −$772M; the largest uses were operating cash flow ($772M) and capital spending ($93.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$177M
Debtnone
Net cash$177M
Cash runway15 months

Lyell Immunopharma is burning cash: its operations consume cash, a free cash flow of −$140M a year at the current rate against $177M of cash and investments: a runway of about 15 months before any new financing.

Where the cash came from and went

Lyell Immunopharma: sources (+) and uses (−) of cash, Q3 2026Lyell Immunopharma: sources (+) and uses (−) of cash, Q3 2026Other investing$53.7MOperating cash flow−$34.6MCash drawn (+) / kept (−)−$19.1MCapital spending−$66KShares issued$41K
Lyell Immunopharma: sources (+) and uses (−) of cash, TTM to Q3 2026Lyell Immunopharma: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$139MOther investing$55.9MOther financing$52.4MCash drawn (+) / kept (−)$31.5MCapital spending−$715KShares issued$109KAsset & business sales$29K

From profit to cash

Lyell Immunopharma: net income to operating cash flow, Q3 2026Lyell Immunopharma: net income to operating cash flow, Q3 2026Net income−$45.5MDepreciation & amortization$2.1MStock-based pay$4.5MPayables$144KAccrued liabilities$6.2MPrepaid and other assets$264KOperating cash flow−$34.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$34.6M−$66K$41K−$19.1M−$34.6M
Q2 2026−$33.9M−$256K—$17.8M−$34.2M
Q1 2026−$38.5M−$89K$26K−$30.6M−$38.6M
Q4 2025−$32.3M−$304K$42K$63.4M−$32.6M
Q3 2025−$28.6M−$62K—−$24.8M−$28.6M
Q2 2025−$34.5M−$168K—$21.6M−$34.6M
Q1 2025−$54.7M−$246K—−$14.7M−$55.0M
Q4 2024−$47.2M−$44K−$1K−$6.7M−$47.3M

Lyell Immunopharma: income statement and cash flow

Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year). The chart follows the revenue to costs, profit and cash.

Lyell Immunopharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.